EGFR and non-small cell lung carcinoma: To speculate that the BIM deletion polymorphism could enhances the acquisition of somatic TKI-resistance mutations in NSCLC cells harboring EGFR mutation, we cultured HCC827 and RERF-Ad-A2 cells (BIM wild-type) or HCC2279 and PC-3 cells (heterozygous for the BIM deletion) with different doses of erlotinib for 72 hours, the cell relative viability was assessed by CCK-8 assays.